In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
In phase 3 clinical trials for ceftobiprole treatment of complicated skin and skin structure infections, 1,219 gram-positive and 276 gram-negative aerobic baseline pathogens were identified. Ceftobiprole inhibited all staphylococcal isolates, including methicillin-resistant strains, at MICs of </=4 mug/ml. Against Enterobacteriaceae and Pseudomonas aeruginosa isolates, the potency of ceftobiprole was similar to that of cefepime.
Amsler
Karen M
KM
Johnson & Johnson Pharmaceutical Research & Development LLC, Raritan, NJ 08869, USA. kamsler@prdus.jnj.com
Davies
Todd A
TA
Shang
Wenchi
W
Jacobs
Michael R
MR
Bush
Karen
K
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002511:Cephalosporins / Q000494:pharmacology*; D004755:Enterobacteriaceae / Q000145:classification / Q000187:drug effects; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D016905:Gram-Negative Bacterial Infections / Q000382:microbiology; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D016908:Gram-Positive Bacterial Infections / Q000382:microbiology; D006801:Humans; D008826:Microbial Sensitivity Tests; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D017192:Skin Diseases, Bacterial / Q000382:microbiology*; D013210:Staphylococcus / Q000145:classification / Q000187:drug effects
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; C443755:ceftobiprole